Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu Sells 20,689 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu sold 20,689 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $16,137.42. Following the transaction, the chief financial officer now directly owns 724,720 shares of the company’s stock, valued at approximately $565,281.60. This represents a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Spero Therapeutics Stock Up 16.4 %

Spero Therapeutics stock opened at $0.88 on Thursday. The company has a market capitalization of $47.81 million, a PE ratio of 12.53 and a beta of 0.61. Spero Therapeutics, Inc. has a 12-month low of $0.74 and a 12-month high of $1.89. The firm’s fifty day moving average is $0.99 and its 200 day moving average is $1.19.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SPRO shares. Evercore ISI cut Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target for the company. in a research note on Friday, December 20th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Spero Therapeutics in a research report on Thursday, January 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. Finally, TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.